Every Team Member is Dedicated to Defeating MASH

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for MASH, a serious liver disease with high unmet medical need.

Kim, patient advocate

About Madrigal

A madrigal is a form of Renaissance choral music known for beautiful harmonies. At Madrigal Pharmaceuticals, our work focuses on restoring balance and harmony to the liver, an organ that performs over 500 different vital functions in the human body.

What began as a small team of researchers in Conshohocken, Pennsylvania, is now a fully integrated biopharmaceutical company with more than 500 employees in the United States and Europe. Madrigal has established the leading clinical development program in MASH.

Our team is united by a single purpose: to lead the fight against MASH.

Our Story

2008

2011

2016

2019

2022

2023

2024

Madrigal Founder and Director, Doctor Rebecca Taub, writes on a whiteboard.

2008

The Madrigal story began in the early 2000s when founder Rebecca Taub, M.D., began applying her unique understanding of liver biology to explore therapies for MASH and metabolic disease. She identified a previously overlooked molecule – a thyroid hormone receptor-β (THR-β) agonist – and founded Madrigal to unlock its potential.

That overlooked molecule would ultimately become resmetirom.

Molecular structure of resmetirom, the active compound in Madrigal’s lead therapy.

2011

Madrigal is incorporated and initiates Phase 1 trial of resmetirom, focusing on safety and tolerability. This early data provides rationale for THR-β agonism’s potential as a therapeutic strategy for liver disease.

2016

Madrigal goes public on the NASDAQ Global Market listed as MDGL.

Phase 2 clinical trial of resmetirom commences, focusing on efficacy and dose optimization. Positive results from this trial in 2018 demonstrate resmetirom’s potential and establish Madrigal’s leadership position in MASH research.

Medical illustration of a liver with visible fibrosis. — *Liver rendering for illustrative purposes only.

2019

Publishes detailed findings from the Phase 2 trial, leading to further study of resmetirom.

Phase 3 pivotal MAESTRO-NASH trial of resmetirom commences.

The late Doctor Stephen Harrison speaks at a conference.

2022

Landmark Phase 3 MAESTRO-NASH topline results are announced. These data propel Madrigal’s growth as it begins building its commercial organization and expands its executive team.

In Memory of Stephen Harrison, M.D.
Principal Investigator of the Phase 3 MAESTRO-NASH study
1969 – 2024

Madrigal CEO, Bill Sibold, speaks to an audience.

2023

In anticipation of a first-to-market launch, Bill Sibold joins Madrigal as CEO to lead the organization into its next chapter as a fully integrated biopharma company.

The FDA grants Breakthrough Therapy Designation and accepts Madrigal’s New Drug Application (NDA) with Priority Review.

2024

Phase 3 MAESTRO-NASH trial results are published in The New England Journal of Medicine.

Madrigal achieves a historic milestone by becoming the first company to achieve U.S. FDA approval for a treatment in MASH.

The Company subsequently launched the treatment in the U.S., with a focus on patients with high unmet need.

Leading the Fight  Against MASH

No family should have to go through the experience of watching a loved one struggle with decompensated cirrhosis or a liver transplant due to MASH. That’s why we aim to develop therapies that will help patients and the health system with this devastating disease.

Our Relentless Pursuit of Innovation

Madrigal has established the leading clinical development program in MASH and delivered the first U.S. FDA-approved treatment in MASH. Because of Madrigal’s success, MASH is no longer a ‘graveyard’ for drug innovation, and we continue to study our medication in additional populations with high unmet need.

Learn About Our Research